Author:
Katayama Satoshi,Hirai Kunihiro
Reference29 articles.
1. Freier SM, Watt AT (2001) Basic principles of antisense drug discovery. In: Crooke ST (ed) Antisense drug technology: principles, strategies, and applications, 2nd edn. Marcel Dekker, New York
2. a) Sharma VK, Sharma RK, Singh SK (2014) Antisense oligonucleotides: modifications and clinical trials. Med Chem Commun 5:1454–1471; b) Sharma VK, Rungta P, Prasad AK (2014) Nucleic acid therapeutics: basic concepts and recent developments. RCS Adv 4:16618–16631
3. Geary RS, Khatsenko O, Bunker K et al (2001) Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther 296:898–904
4. a) Campbell MA, Wengel J (2011) Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev 40:5680–5689; b) Kaur H, Babu BR, Maiti S (2007) Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA) Chem Rev 107:4672–4697; c) Obika S (2004) Development of bridged nucleic acid analogues for antigene technology. Chem Pharm Bull 52:1399–1404
5. Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187–195
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献